Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00711243 · ClinicalTrials.gov registry record · Phase 1

Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor

A Phase 1 study of Gastric Cancer and Unspecified Adult Solid Tumor, Protocol Specific, sponsored by Northwestern University.

Completed
Registry status
Phase 1
Development phase
59
Enrollment target
1
Study location

NCT00711243 is a Phase 1 study of Gastric Cancer and Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by Northwestern University. The registered enrollment target is 59 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00711243, a Phase 1 study of Gastric Cancer and Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by Northwestern University.

COMPLETED
Registry status
Phase 1
Development phase
59 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel, oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of docetaxel when given with oxaliplatin and fluorouracil and to see how well they work in treating patients with metastatic or unresectable stomach cancer, gastroesophageal junction cancer, or other solid tumor.

Conditions Studied

Gastric Cancer Unspecified Adult Solid Tumor, Protocol Specific

Interventions

  • DRUG docetaxel
  • DRUG oxaliplatin
  • DRUG fluorouracil

Study Locations (1)

Illinois

  • Robert H. Lurie Comprehensive Cancer Center at Northwestern University - Chicago

Trial Details

FieldValue
Enrollment Target 59 participants
Start Date 2005-04-20
Est. Completion 2011-02-25
Phase Phase 1

Sponsor

Northwestern University

1,209 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00711243

The ClinicalTrials.gov registry entry for NCT00711243 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (82% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 3 interventions - of which docetaxel is the first listed.

NCT00711243 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT00711243 about?

NCT00711243 is a clinical study titled "Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor". RATIONALE: Drugs used in chemotherapy, such as docetaxel, oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: ...

What is the current status of trial NCT00711243?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2005-04-20. Estimated completion is 2011-02-25.

What conditions does trial NCT00711243 study?

This clinical trial studies the following conditions: Gastric Cancer, Unspecified Adult Solid Tumor, Protocol Specific.

What interventions are being tested in trial NCT00711243?

The interventions under investigation include: docetaxel (DRUG), oxaliplatin (DRUG), fluorouracil (DRUG).

Who is sponsoring clinical trial NCT00711243?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00711243 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastric Cancer

All registered trials for this condition

Unspecified Adult Solid Tumor, Protocol Specific

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.